Centers for Disease Control and Prevention Appoints Stephan Monroe as Director for Laboratory Science and Safety
Sep 16 15
Centers for Disease Control and Prevention announced that Stephan Monroe, who has been the CDC's acting associate director for laboratory science and safety since May 2015, is being permanently appointed to the position.
Accelerate Diagnostics Announces Research Collaboration with U.S. Centers for Disease Control and Prevention for Early Detection of Antibiotic-Resistant Biothreat Agents
Nov 3 14
Accelerate Diagnostics, Inc. announced that it has entered into a research collaboration with the Rapid Antimicrobial Susceptibility Testing Laboratory at the U.S. Centers for Disease Control and Prevention (CDC) to develop tests for the rapid analysis of antibiotic-resistant biothreat agents based on Accelerate's high-speed identification and antibiotic susceptibility testing platform. Bacterial, biothreat agents and diseases such as anthrax, tularemia and plague pose significant national security and public health risks. While infections with these pathogens are rare in the United States, they can be disseminated or transmitted from person-to-person and result in high mortality rates. They therefore require special public health preparedness and surveillance so that any potential biothreat activity or disease outbreaks can be rapidly identified and contained. Early detection, isolation and treatment with effective antibiotics are critical to cure patients and limit the spread of disease. Unfortunately, conventional testing methods available in hospital and public health labs can take several days to produce results. These methods are therefore unable to provide critical, time sensitive information to the healthcare community, denying caregivers the opportunity to manage infection and prevent outbreaks at the earliest stage. Accelerate Diagnostics is developing a fully integrated, easy-to-use platform that provides high-speed identification and antibiotic susceptibility testing of pathogens, working directly from patient samples. The platform enables laboratories to provide critical microbiology results in hours instead of days. As part of the collaboration with the CDC laboratory, Accelerate Diagnostics will use its expertise to develop assays for rapid identification of key bacterial biothreat agents, their virulence markers, and their antibiotic susceptibility and resistance profiles. The CDC will provide scientific expertise on the microbiology and molecular biology of biothreat agents, and will evaluate and optimize the performance of the platform, using its collection of biothreat agents. As part of the agreement, the CDC has purchased the Accelerate ID/AST platform for use in their laboratory.
Centers for Disease Control and Prevention Elects Ruth Katz to the Board of Directors
Mar 26 14
Ruth Katz, J.D., M.P.H., has been elected to the board of directors of the Centers for Disease Control and Prevention (CDC) Foundation. Katz is the director of The Aspen Institute's Health, Medicine and Society (HMS) Program, an educational and policy studies organization. The HMS Program draws on the expertise of a diverse group of leaders in health and health policy to inform the national conversation on health, medicine and biomedical research. Katz has a long and distinguished career in public health and previously served as a member and secretary of the CDC Foundation's board of directors from 2004-2009.